India has the highest number of asthma sufferers in the Asia-Pacific (APAC) region. In 2014, 53.6 million people were estimated to be living with the disease, which is approximately 52.4% of the total assessed APAC prevalence. Lack of knowledge of the condition among the public, an increasing aging population, and increasing air and dust pollution will mean the prevalence rate will continue to rise over the period, resulting in 57 million sufferers by 2021. Despite this, India only represented 12.2% of the APAC asthma market, which reflects the low cost of therapy in comparison with the other assessed countries. Japan, by contrast, was the largest market of the five APAC countries in 2014 at $1.8 billion, and will continue its lead to 2021, growing to $3 billion at a CAGR of 7.1%, this reflects the relatively high cost of drugs, and the country’s readiness to adopt promising new molecules such as the IL-targeting mAbs.
GBI Research’s Asthma Therapeutics in Asia-Pacific Markets to 2021 – High Prevalence and Launch of Late-Stage Biologics will Drive the Market in Spite of Affordability Concerns report provides analysis of asthma treatment space across the Asia-Pacific region, including China, India, Australia, South Korea, and Japan. It includes annualized market data from 2014 and forecast to 2021, as well as epidemiology trends and information on new market entrants.
Published: March 2016, Single User Price: $4,995